Immunotherapy and Immunomodulation in Myeloproliferative Neoplasms

Hematol Oncol Clin North Am. 2021 Apr;35(2):409-429. doi: 10.1016/j.hoc.2020.12.007. Epub 2021 Feb 2.

Abstract

Myeloproliferative neoplasms are characterized by chronic inflammation. The discovery of constitutively active JAK-STAT signaling associated with driver mutations has led to clinical and translational breakthroughs. Insights into the other pathways and novel factors of potential importance are being actively investigated. Various classes of agents with immunomodulating or immunosuppressive properties have been used with varying degrees of success in treating myeloproliferative neoplasms. Early clinical trials are investigating the feasibility, effectiveness, and safety of immune checkpoint inhibitors, cell-based immunotherapies, and SMAC mimetics. The dynamic landscape of immunotherapy and immunomodulation in myeloproliferative neoplasms is the topic of the present review.

Keywords: IMiD; Immunotherapy; Interferon ICI; JAK-STAT; MPN.

Publication types

  • Review

MeSH terms

  • Humans
  • Immune Checkpoint Inhibitors / therapeutic use
  • Immunotherapy*
  • Janus Kinase 2 / metabolism
  • Myeloproliferative Disorders* / therapy
  • Neoplasms* / therapy
  • STAT Transcription Factors
  • Signal Transduction

Substances

  • Immune Checkpoint Inhibitors
  • STAT Transcription Factors
  • Janus Kinase 2